PDE4 inhibitors and chronic obstructive pulmonary disease

Emerging Drugs

Volumn 5, Issue 3, 2000, Pages 309-319

  Wolda, S L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

COPD; Inflammatory diseases; PDE4 inhibitors

Indexed keywords

3 (3 CYCLOPENTYLOXY 4 METHOXYBENZYL) 6 ETHYLAMINO 8 ISOPROPYL 3H PURINE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 4 [6,7 DIETHOXY 2,3 BIS(HYDROXYMETHYL) 1 NAPHTHYL] 1 (2 METHOXYETHYL) 2(1H) PYRIDINONE; ANTIBIOTIC AGENT; ATIZORAM; BAY 19 8004; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CDC 801; CHOLINERGIC RECEPTOR BLOCKING AGENT; CI 1018; CILOMILAST; CIPAMFYLLINE; CORTICOSTEROID; D 4418; DIGOXIN; DIURETIC AGENT; ETANERCEPT; EXPECTORANT AGENT; N (3,5 DICHLORO 4 PYRIDYL) [1 (4 FLUOROBENZYL) 5 HYDROXY 3 INDOLYL]GLYOXYLIC ACID AMIDE; PD 189659; PDA 641; PHOSPHODIESTERASE IV INHIBITOR; RETINOIC ACID; ROFLUMILAST; RS 113456; SALMETEROL; SIVELESTAT; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASTHMA; ATOPIC DERMATITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CROHN DISEASE; DRUG CHOICE; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; EMPHYSEMA; HEALTH CARE COST; HEART RIGHT VENTRICLE FAILURE; HUMAN; LUNG TRANSPLANTATION; MORTALITY; NONHUMAN; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME;

EID: 0033777704     PISSN: 13619195     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.5.3.309     Document Type: Review

References (56)

1. Standards for the diagnosis and care of patents with chronic obstructive pulmonary disease
2. A consensus statement of the European Respiratory Society. Optimal assessment and management of chronic obstructive pulmonary disease (COPD)
3. Summary of COPD guidelines
4. Structural and inflammatory changes in COPD: A comparison with asthma
5. Airway inflammation in chronic obstructive pulmonary disease
6. Are inhaled glucocorticosteroids effective in chronic obstructive pulmonary disease?
7. Type 4 phosphodiesterase inhibitors and their potential in the treatment of inflammatory disease
8. Neutrophils and protease/antiprotease imbalance
9. Novel approaches and targets for treatment of chronic obstructive pulmonary disease
10. Trends in the US COPD therapeutics market
11. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD
12. Impact of COPD on lung health worldwide; Epidemiology and incidence
13. Economic burden of COPD
14. Neutrophil elastase inhibitor, ONO-5046 suppresses ozone-induced airway mucous hypersecretion in guinea pigs
15. Protective effects of ONO-5046*Na, a specific neutrophil elastase inhibitor, on postperfusion lung injury
16. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice
17. Alpha-1-antitrypsin and the synthetic metalloprotease inhibitor RS113456 prevent dust induced connective tissue breakdown by suppressing the inflammatory response
18. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats
19. A Phase II pilot study of all-trans retinoic acid for the treatment of human emphysema
20. Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here?
21. Molecular cloning and characterisation of a distinct human phosphodiesterase gene family: PDE11A
22. The molecular biology of cyclic nucleotide phosphodiesterases
23. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD)
24. Cyclic nucleotide phosphodiesterase Type IV participates in the regulation of IL-10 and in the subsequent in TNF-alpha and IL-6 release by endotoxin-stimulated macrophages
25. Suppression of the acute inflammatory response of porcine alveolar - and liver macrophages
26. Ariflo(TM) (SB207499) is a potent inhibitor of leukotriene B4-induced mobilization of peripheral neutrophils in rabbits
27. Salmeterol and inhibitors of phosphodiesterase 4 (PDE4) induce apoptosis in neutrophils from asthmatics
28. Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis
29. The efficacy of Ariflo (SB 207499) a second-generation, oral PDE4 inhibitor, in patients with COPD
30. Ariflo (SB 207499) a second-generation, oral PDE4 inhibitor, improves quality of life in patients with COPD
31. TNF-alpha inhibitors and rheumatoid arthritis
32. The future role of anti-tumour necrosis factor-alpha products in the treatment of Crohn's disease
33. The role of tumor necrosis factor in the pathophysiology of heart failure
34. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure
35. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies
36. PDE4 inhibitors 1999
37. Safety and efficacy of the new PDE4 inhibitor roflumilast administered to patients with exercise-induced asthma over 4 weeks
38. Pharmacodynamic-pharmacokinetic (PD/PK) profile of the phosphodiesterase (PDE) 4 inhibitor, V11294A, in human volunteers
39. Mediators Inflamm
40. Novel generation phosphodiesterase 4 inhibitors for the treatment of asthma
41. The evaluation of a selective phosphodiesterase (PDE) 4 inhibitor BAY 19-8004, in guinea pig antigen challenge and ferret emesis models
42. Molecular and cellular profile of the structurally novel phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004
43. Differential distribution of mRNA encoding cAMP-specific phosphodiesterase isoforms in the rat brain
44. Palladium-catalysed cross-coupling reactions for the synthesis of 6,8-disubstituted 1,7-naphthridines: A novel class of potent and selective phosphodiesterase Type 4D inhibitors
45. Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition
46. Specific CD3 epsilon association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation
47. Deaths: Selected causes (International Classification) and sex, onwards (England and Wales)